NCT04048278RecruitingEarly phase 1
Lidocaine Infusion in Pancreatic Cancer
Lidocaine Infusion in Pancreatic Cancer: Translational Studies in a Preclinical Model And Human Subjects
Source: ClinicalTrials.gov · Last updated 15 Jun 2026
Brief summary (registry, in English)
This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic pancreatectomy for all types of pancreatic cancer. A prospective randomized controlled double blinded trial design will be used for the proposed study.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- First submitted
- 18 Jun 2019
- Start date
- Nov 2018
- Primary completion date
- Nov 2027
- Lead sponsor
- University of Illinois Chicago
- Diseases
- Pancreatic cancer
- NCT number
- NCT04048278
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 46
- From Nov 2018 to the primary completion date, Nov 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Is currently being treated with any of the following class I antiarrhythmic drugs; quinidine, flecainide, disopyramide, or procainamide
- Has been treated with amiodarone in the past
Other illness
- Has hypersensitivity or allergy to amide-linked local anesthetics
- Has a second or third degree heart block
- Has Adams-Stoke syndrome
- Has Wolff-Parkinson-White syndrome
- Has a history of blood clots, pulmonary embolism, or deep vein thrombosis unless controlled by anticoagulant treatment
- Has a known history of human immunodeficiency virus (HIV) positivity or untreated and uncontrolled hepatitis B or C
Other
- Has American Society of Anesthesiologists (ASA) physical status \> 3
- Has severe sinoatrial block
Who the study is looking for
- Has histologically or cytologically confirmed adenocarcinoma of the pancreas that is considered resectable as well as other types of pancreatic cancer (malignant endocrine and exocrine tumors)
- Has measurable disease, defined as at least 1 tumor that fulfills the criteria
- Patients diagnosed with resectable cancer, but upon initial phase of surgical exploration found to have metastatic disease
- Has read, understood and signed the informed consent form (ICF) approved by the Independent Review Board/Independent Ethics Committee (IRB/IEC)
- Prior systemic treatments for metastatic disease are permitted, including targeted therapies, biologic response modifiers, chemotherapy, hormonal therapy, or investigational therapy.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Illnois at Chicago Coordinator of this site? Confirm its status | Chicago | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.